Chronic Hand Eczema Market Projected to Grow by 2034 | LEO Pharma, Japan Tobacco, Asana Biosciences Expected to Drive Market Expansion - DelveInsight

The growth of the chronic hand eczema market is fueled by rising disease prevalence, increased research and development investments, and the introduction of new therapies during the forecast period from 2020 to 2034.

The market report provides detailed insights into chronic hand eczema, including market size, share, epidemiology, emerging treatments, key drivers and challenges, ongoing clinical trials, strategic collaborations, and the adoption of therapies by leading companies actively contributing to market growth.

Some of the key highlights from the Chronic Hand Eczema Market Insights Report:

Several leading pharmaceutical companies, including LEO Pharma, Japan Tobacco, Asana Biosciences, and others, are actively developing innovative therapies to improve the treatment landscape for chronic hand eczema (CHE). According to DelveInsight, the CHE market is expected to undergo notable growth during the forecast period (2024-2034), driven by advancements in medical research, improved diagnostics, and the introduction of new therapies.
In September 2024, LEO Pharma made two significant announcements:
The U.S. FDA accepted the New Drug Application (NDA) for delgocitinib cream 20 mg/g (2%) to treat adults with moderate to severe CHE, especially for those unresponsive to or unable to use topical corticosteroids.

The European Commission (EC) granted marketing authorization for Anzupgo® (delgocitinib) cream, offering a new treatment option for adult patients in Europe with moderate to severe CHE where conventional corticosteroids have proven ineffective. These milestones highlight LEO Pharma's leadership in dermatology and expand treatment options for CHE patients.

In 2023, the U.S. CHE market was valued at approximately USD 431 million. Within the EU4 and the UK, Germany had the largest market size at around USD 71 million, followed by France (USD 46 million) and the UK (USD 45 million). Germany also recorded the highest number of cases (~493,000), with France and the UK at approximately 321,000 and 317,000 cases, respectively. In the U.S., nearly 1 million cases were diagnosed, a figure expected to rise by 2034 due to environmental and lifestyle factors such as weather conditions, stress, and poor skincare habits.
Chronic hand eczema is more prevalent among females, largely due to increased exposure to irritants from household and skincare products. In 2023, the U.S. had about 1 million female cases and 993,000 male cases. In the UK, cases were distributed across age groups as follows: 52,000 (20-29 years), 98,000 (30-49 years), 29,000 (50-69 years), and 26,000 (70+ years).
In Japan, CHE accounted for roughly 15% of global cases in 2023. Among subtypes, irritant contact eczema was most common (~27%), while fingertip eczema was least prevalent (~4%). Cases are projected to rise by 2034 due to modern lifestyle factors like stress, poor diet, and sedentary behavior, which exacerbate inflammatory skin conditions.
Companies such as Regeneron, Sanofi, Stiefel Laboratories, and Asana Biosciences are actively exploring potential CHE treatments expected to enter the market during the forecast period (2024-2034).

Strategise your business goals by understanding market dynamics @ Chronic Hand Eczema Market Landscape @ https://www.delveinsight.com/report-store/chronic-hand-eczema-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kritikapr

Chronic Hand Eczema Overview

Chronic hand eczema is a prevalent inflammatory skin disorder characterized by dry, red, itchy, and often painful patches on the hands. The condition can occur in cycles of flare-ups and remissions or persist continuously. Its causes include genetic predisposition, environmental triggers such as irritants and allergens, frequent handwashing, and stress. Chronic hand eczema can significantly affect daily life, causing both physical discomfort and emotional distress.

Diagnosis involves a detailed medical history, physical examination, and sometimes additional tests. Healthcare providers evaluate symptoms, the appearance of the skin, and potential triggers related to lifestyle or occupational exposures. Patch testing may be conducted to identify specific allergens, while other conditions like psoriasis, fungal infections, or contact dermatitis are ruled out. An accurate diagnosis is essential for creating a personalized treatment plan that effectively manages the condition.

Do you know the treatment paradigms for different countries? Download our Chronic Hand Eczema Market Sample Report @ https://www.delveinsight.com/sample-request/chronic-hand-eczema-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kritikapr

Chronic Hand Eczema Epidemiology Segmentation

DelveInsight's Chronic Hand Eczema market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Chronic Hand Eczema historical patient pools and forecasted Chronic Hand Eczema patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Chronic Hand Eczema Market report proffers epidemiological analysis for the study period 2020-32 in the 7MM segmented into:

Chronic Hand Eczema Prevalence
Age-Specific Chronic Hand Eczema Prevalence
Gender-Specific Chronic Hand Eczema Prevalence
Diagnosed and Treatable Cases of Chronic Hand Eczema

Visit for more @ Chronic Hand Eczema Epidemiological Insights @ https://www.delveinsight.com/report-store/chronic-hand-eczema-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kritikapr

Chronic Hand Eczema Market Insights

A variety of medications are commonly employed to manage chronic hand eczema. Topical corticosteroids serve as the first-line therapy, reducing inflammation, itching, and swelling during flare-ups, though they are typically used short-term to minimize side effects such as skin thinning. Topical calcineurin inhibitors (e.g., tacrolimus and pimecrolimus) are effective alternatives, particularly for sensitive areas like the hands and face, as they modulate the skin's immune response.

Emollients and moisturizers play a vital role in daily care by repairing the skin barrier, retaining moisture, and preventing irritation and flare-ups. Topical immunomodulators, such as crisaborole, are also used to manage inflammation, especially when corticosteroids or calcineurin inhibitors are unsuitable or ineffective. These therapies are often combined to create a more personalized and effective treatment strategy for managing the condition.
Chronic Hand Eczema Market Outlook
The management of chronic hand eczema largely depends on topical therapies-including corticosteroids, calcineurin inhibitors, and moisturizers-to relieve symptoms, reduce inflammation, and restore the skin barrier. In more severe cases, systemic treatments, such as oral medications or biologics, may be utilized. The chronic hand eczema treatment market continues to evolve, driven by advances in medical knowledge, the introduction of innovative therapies, changing patient expectations, greater awareness among healthcare providers and patients, and the influence of environmental and lifestyle factors.
Chronic Hand Eczema Marketed Drugs
TOCTINO (alitretinoin): Basilea Pharmaceutica/ Stiefel Laboratories
Chronic Hand Eczema Emerging Drugs
ARQ-252: Arcutis Biotherapeutics
Delgocitinib: LEO Pharma/Japan Tobacco
Chronic Hand Eczema Key Companies
LEO Pharma
Japan Tobacco
Asana Biosciences
And others
For more information, visit Chronic Hand Eczema Market Analysis, Patient Pool, and Emerging Therapies @ https://www.delveinsight.com/sample-request/chronic-hand-eczema-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kritikapr

Scope of the Chronic Hand Eczema Market Report:

11 Years Forecast
7MM Coverage
Descriptive overview of Chronic Hand Eczema, causes, signs and symptoms, diagnosis, treatment
Comprehensive insight into Chronic Hand Eczema epidemiology in the 7MM
Chronic Hand Eczema marketed and emerging therapies
Chronic Hand Eczema companies
Chronic Hand Eczema market drivers and barriers

Table of Contents:

1 Chronic Hand Eczema Market Key Comprehensive Insights
2 Chronic Hand Eczema Market Report Introduction
3 Competitive Intelligence Analysis for Chronic Hand Eczema
4 Chronic Hand Eczema Market Analysis Overview at a Glance
5 Executive Summary of Chronic Hand Eczema
6 Chronic Hand Eczema Epidemiology and Market Methodology
7 Chronic Hand Eczema Epidemiology and Patient Population
8 Chronic Hand Eczema Patient Journey
9 Chronic Hand Eczema Treatment Algorithm, Chronic Hand Eczema Current Treatment, and Medical Practices
10 Key Endpoints in Chronic Hand Eczema Clinical Trials
11 Chronic Hand Eczema Marketed Therapies
12 Chronic Hand Eczema Emerging Therapies
13 Chronic Hand Eczema: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Chronic Hand Eczema
16 Chronic Hand Eczema Market Key Opinion Leaders Reviews
18 Chronic Hand Eczema Market Drivers
19 Chronic Hand Eczema Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight

Related Reports:

Chronic Hand Eczema Epidemiology 2034

DelveInsight's "Chronic Hand Eczema - Epidemiology Forecast to 2034" report delivers an in-depth understanding of the disease, historical and forecasted Chronic Hand Eczema epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Chronic Hand Eczema Pipeline 2024

"Chronic Hand Eczema Pipeline Insights, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Chronic Hand Eczema market. A detailed picture of the Chronic Hand Eczema pipeline landscape is provided, which includes the disease overview and Chronic Hand Eczema treatment guidelines.

Contact Info:

Kritika Rehani, Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.